United States Biotechnology & Medical Research

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc. experienced significant insider trading activity on March 19, 2025, when Biotech Growth N.V. executed multiple large-scale share sales. These transactions represent the most recent recorded movements. No further activity occurred within the last three months, indicating a period of relative quiet regarding equity changes by company insiders.
Ticker: BDTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Black Diamond Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Sale
Price
473.25
Quantity 41,726 +38.7%
Value US$3,271,116
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Sale
Price
377.47
Quantity 74,034 +9.8%
Value US$1,540,083
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Sale
Price
156.41
Quantity 86,100 +0.1%
Value US$4,135,493
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Sale
Price
2.00
Quantity 2,000,000 -32.2%
Value US$4,000,800
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Sale
Price
2.31
Quantity 1,000,000 -13.9%
Value US$2,308,100
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Sale
Price
1.94
Quantity 300,000 -4.0%
Value US$582,900
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Sale
Price
2.07
Quantity 1,000,000 -11.7%
Value US$2,069,100
David Epstein Former Employer
Transaction date
Proposed sale
Price
6.20
Quantity 50,000
Value US$310,000
David Epstein Former Employee
Transaction date
Proposed sale
Price
6.20
Quantity 50,000
Value US$310,000
David Epstein Former Employer
Transaction date
Proposed sale
Price
6.25
Quantity 50,000
Value US$312,500
David Epstein Former Employer
Transaction date
Proposed sale
Price
5.00
Quantity 69,024
Value US$345,120
David Esptein Former Employee
Transaction date
Proposed sale
Price
4.80
Quantity 75,000
Value US$360,000
David Epstein Former Employer
Transaction date
Proposed sale
Price
5.00
Quantity 50,000
Value US$250,000
David Epstein Former Board Member
Transaction date
Proposed sale
Price
4.70
Quantity 40,353
Value US$189,659
David Epstein Former Board Member
Transaction date
Proposed sale
Price
4.70
Quantity 9,647
Value US$45,341
David Epstein Former Board Member
Transaction date
Proposed sale
Price
5.02
Quantity 6,011
Value US$30,175
David Epstein Former Board Member
Transaction date
Proposed sale
Price
5.00
Quantity 743
Value US$3,715
David Epstein Former board member
Transaction date
Proposed sale
Price
5.02
Quantity 20,143
Value US$101,118
Leah Wu Spouse of former board member
Transaction date
Proposed sale
Price
5.02
Quantity 20,268
Value US$101,745
David Epstein Former Board Member
Transaction date
Proposed sale
Price
5.45
Quantity 2,951
Value US$16,083
David Epstein Former Board Member
Transaction date
Proposed sale
Price
6.03
Quantity 24,621
Value US$148,465
David Epstein Former Board Member
Transaction date
Proposed sale
Price
6.15
Quantity 70,853
Value US$435,746
David Epstein Former Board Member
Transaction date
Proposed sale
Price
6.14
Quantity 62,528
Value US$383,922
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
2.34
Quantity 400,000 +4.9%
Value US$934,080
1.6
Behbahani Ali Non-Executive Director
Transaction date
Purchase
Price
5.00
Quantity 1,000,000 +29.0%
Value US$5,000,000
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
5.00
Quantity 1,000,000 +14.0%
Value US$5,000,000
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
5.49
Quantity 1,740,000 +32.4%
Value US$9,555,036
Epstein David M. SEE REMARKS Executive Director
Transaction date
Planned sale
Price
6.70
Quantity 25,000 -3.6%
Value US$167,500
Epstein David M. Officer Officer
Transaction date
Proposed sale
Price
6.70
Quantity 25,000
Value US$167,500
3.6
Ni Fang SEE REMARKS Officer
Transaction date
Purchase
Price
1.28
Quantity 36,363 +40.8%
Value US$46,596
3.6
Ni Fang SEE REMARKS Officer
Transaction date
Purchase
Price
1.29
Quantity 20,000 +29.0%
Value US$25,770
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
2.25
Quantity 99,801 +1.9%
Value US$224,912
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
2.18
Quantity 172,974 +3.4%
Value US$376,962
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
1.87
Quantity 191,678 +3.9%
Value US$359,224
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
1.51
Quantity 87,850 +1.8%
Value US$132,750
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
1.42
Quantity 53,734 +1.1%
Value US$76,345
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
1.32
Quantity 77,689 +1.7%
Value US$102,775
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
2.57
Quantity 255,711 +5.8%
Value US$657,868
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
2.66
Quantity 150,000 +3.5%
Value US$399,480
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
3.24
Quantity 150,000 +3.6%
Value US$486,645
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
3.29
Quantity 150,000 +3.8%
Value US$493,935
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
3.57
Quantity 102,556 +2.6%
Value US$366,217
2.1
BIOTECH GROWTH N V Large shareholder
Transaction date
Purchase
Price
3.42
Quantity 150,000 +4.0%
Value US$513,600
Roberts Christopher D. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
26.64
Quantity 2,500 -43.9%
Value US$66,602
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
25.00
Quantity 4,078 -32.7%
Value US$101,950
Roberts Christopher D. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.54
Quantity 2,500 -43.9%
Value US$63,848
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
26.36
Quantity 4,078 -32.7%
Value US$107,493
Roberts Christopher D. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
26.57
Quantity 884 -21.6%
Value US$23,484
Roberts Christopher D. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.85
Quantity 1,616 -28.4%
Value US$41,778
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
27.66
Quantity 307 -3.5%
Value US$8,492
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
27.19
Quantity 3,771 -30.2%
Value US$102,533
Roberts Christopher D. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
25.35
Quantity 2,500 -43.9%
Value US$63,375
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
36.00
Quantity 7,511 -47.2%
Value US$270,395
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
34.13
Quantity 100 -0.6%
Value US$3,412
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
32.50
Quantity 103 -0.6%
Value US$3,347
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
31.91
Quantity 147 -0.9%
Value US$4,690
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
30.50
Quantity 1,669 -9.3%
Value US$50,912
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
29.92
Quantity 2,048 -10.3%
Value US$61,284
2.4
Leggett Thomas Chief Financial Officer Officer
Transaction date
Planned sale
Price
33.94
Quantity 3,000 -100.0%
Value US$101,820
Roberts Christopher D. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
31.78
Quantity 537 -14.4%
Value US$17,065
Roberts Christopher D. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
31.31
Quantity 1,963 -34.4%
Value US$61,460
Epstein David M. See Remarks Executive Director
Transaction date
Planned sale
Price
31.80
Quantity 2,015 -0.3%
Value US$64,075
Epstein David M. See Remarks Executive Director
Transaction date
Planned sale
Price
30.99
Quantity 9,985 -1.4%
Value US$309,430
Hatzis-Schoch Brent See Remarks Officer
Transaction date
Planned sale
Price
34.95
Quantity 4,078 -57.6%
Value US$142,522
2.4
Leggett Thomas Chief Financial Officer Officer
Transaction date
Planned sale
Price
34.05
Quantity 1,941 -100.0%
Value US$66,094
2.4
Leggett Thomas Chief Financial Officer Officer
Transaction date
Planned sale
Price
33.27
Quantity 1,059 -35.3%
Value US$35,233
Roberts Christopher D. Chief Scientific Officer Officer
Transaction date
Planned sale
Price
32.42
Quantity 2,500 -100.0%
Value US$81,055
Epstein David M. See Remarks Executive Director
Transaction date
Planned sale
Price
33.45
Quantity 1,077 -0.2%
Value US$36,021
Epstein David M. See Remarks Executive Director
Transaction date
Planned sale
Price
32.64
Quantity 10,923 -1.5%
Value US$356,553
3.2
Bolzon Bradley J PhD Non-Executive Director Large shareholder
Transaction date
Planned sale
Price
34.16
Quantity 200 -0.0%
Value US$6,833
3.2
Bolzon Bradley J PhD Non-Executive Director Large shareholder
Transaction date
Planned sale
Price
33.13
Quantity 10,193 -1.2%
Value US$337,680
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
41,726 +38.7%
473.25
US$3,271,116 		41,726 +38.7% 473.25 US$3,271,116
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
74,034 +9.8%
377.47
US$1,540,083 		74,034 +9.8% 377.47 US$1,540,083
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
86,100 +0.1%
156.41
US$4,135,493 		86,100 +0.1% 156.41 US$4,135,493
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
2,000,000 -32.2%
2.00
US$4,000,800 		2,000,000 -32.2% 2.00 US$4,000,800
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
1,000,000 -13.9%
2.31
US$2,308,100 		1,000,000 -13.9% 2.31 US$2,308,100
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
300,000 -4.0%
1.94
US$582,900 		300,000 -4.0% 1.94 US$582,900
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
1,000,000 -11.7%
2.07
US$2,069,100 		1,000,000 -11.7% 2.07 US$2,069,100
2024-08-30 2024-08-28 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
221,600 -5.6%
6.32
US$1,400,556 		221,600 -5.6% 6.32 US$1,400,556
2024-07-31 2024-07-31 PrS Proposed sale
David Epstein

Former Employer
50,000
6.20
US$310,000 		50,000 6.20 US$310,000
2024-07-26 2024-07-26 PrS Proposed sale
David Epstein

Former Employee
50,000
6.20
US$310,000 		50,000 6.20 US$310,000
2024-07-16 2024-07-16 PrS Proposed sale
David Epstein

Former Employer
50,000
6.25
US$312,500 		50,000 6.25 US$312,500
2024-07-11 2024-07-11 PrS Proposed sale
David Epstein

Former Employer
69,024
5.00
US$345,120 		69,024 5.00 US$345,120
2024-07-09 2024-07-09 PrS Proposed sale
David Esptein

Former Employee
75,000
4.80
US$360,000 		75,000 4.80 US$360,000
2024-06-28 2024-06-28 PrS Proposed sale
David Epstein

Former Employer
50,000
5.00
US$250,000 		50,000 5.00 US$250,000
2024-06-27 2024-06-27 PrS Proposed sale
David Epstein

Former Board Member
40,353
4.70
US$189,659 		40,353 4.70 US$189,659
2024-06-26 2024-06-26 PrS Proposed sale
David Epstein

Former Board Member
9,647
4.70
US$45,341 		9,647 4.70 US$45,341
2024-06-24 2024-06-24 PrS Proposed sale
David Epstein

Former Board Member
6,011
5.02
US$30,175 		6,011 5.02 US$30,175
2024-06-21 2024-06-21 PrS Proposed sale
David Epstein

Former Board Member
743
5.00
US$3,715 		743 5.00 US$3,715
2024-06-20 2024-06-20 PrS Proposed sale
David Epstein

Former board member
20,143
5.02
US$101,118 		20,143 5.02 US$101,118
2024-06-20 2024-06-20 PrS Proposed sale
Leah Wu

Spouse of former board member
20,268
5.02
US$101,745 		20,268 5.02 US$101,745
2024-06-18 2024-06-18 PrS Proposed sale
David Epstein

Former Board Member
2,951
5.45
US$16,083 		2,951 5.45 US$16,083
2024-06-14 2024-06-14 PrS Proposed sale
David Epstein

Former Board Member
24,621
6.03
US$148,465 		24,621 6.03 US$148,465
2024-06-13 2024-06-13 PrS Proposed sale
David Epstein

Former Board Member
70,853
6.15
US$435,746 		70,853 6.15 US$435,746
2024-06-12 2024-06-12 PrS Proposed sale
David Epstein

Former Board Member
62,528
6.14
US$383,922 		62,528 6.14 US$383,922
2023-10-19 2023-10-17 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
400,000 +4.9%
2.34
US$934,080 		400,000 +4.9% 2.34 US$934,080
2023-07-07 2023-07-05 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director
935,850 +41.1%
5.00
US$4,679,250 		935,850 +41.1% 5.00 US$4,679,250
2023-07-06 2023-07-05 B Purchase
1.6
Behbahani Ali
Non-Executive Director
1,000,000 +29.0%
5.00
US$5,000,000 		1,000,000 +29.0% 5.00 US$5,000,000
2023-07-03 2023-06-30 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
1,000,000 +14.0%
5.00
US$5,000,000 		1,000,000 +14.0% 5.00 US$5,000,000
2023-06-29 2023-06-27 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
1,740,000 +32.4%
5.49
US$9,555,036 		1,740,000 +32.4% 5.49 US$9,555,036
2023-06-28 2023-06-27 PlS Planned sale
Epstein David M.

SEE REMARKS

Executive Director
25,000 -3.6%
6.70
US$167,500 		25,000 -3.6% 6.70 US$167,500
2023-06-27 2023-06-27 PrS Proposed sale
Epstein David M.

Officer

Officer
25,000
6.70
US$167,500 		25,000 6.70 US$167,500
2022-12-23 2022-12-22 B Purchase
3.6
Ni Fang

SEE REMARKS

Officer
36,363 +40.8%
1.28
US$46,596 		36,363 +40.8% 1.28 US$46,596
2022-12-23 2022-12-21 B Purchase
3.6
Ni Fang

SEE REMARKS

Officer
20,000 +29.0%
1.29
US$25,770 		20,000 +29.0% 1.29 US$25,770
2022-11-02 2022-10-31 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
99,801 +1.9%
2.25
US$224,912 		99,801 +1.9% 2.25 US$224,912
2022-10-31 2022-10-28 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
172,974 +3.4%
2.18
US$376,962 		172,974 +3.4% 2.18 US$376,962
2022-10-31 2022-10-27 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
191,678 +3.9%
1.87
US$359,224 		191,678 +3.9% 1.87 US$359,224
2022-10-25 2022-10-21 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
87,850 +1.8%
1.51
US$132,750 		87,850 +1.8% 1.51 US$132,750
2022-10-21 2022-10-20 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
53,734 +1.1%
1.42
US$76,345 		53,734 +1.1% 1.42 US$76,345
2022-10-21 2022-10-19 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
77,689 +1.7%
1.32
US$102,775 		77,689 +1.7% 1.32 US$102,775
2022-04-29 2022-04-28 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
255,711 +5.8%
2.57
US$657,868 		255,711 +5.8% 2.57 US$657,868
2022-04-29 2022-04-27 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
150,000 +3.5%
2.66
US$399,480 		150,000 +3.5% 2.66 US$399,480
2022-04-20 2022-04-19 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
150,000 +3.6%
3.24
US$486,645 		150,000 +3.6% 3.24 US$486,645
2022-04-20 2022-04-18 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
150,000 +3.8%
3.29
US$493,935 		150,000 +3.8% 3.29 US$493,935
2022-04-14 2022-04-13 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
102,556 +2.6%
3.57
US$366,217 		102,556 +2.6% 3.57 US$366,217
2022-04-14 2022-04-12 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
150,000 +4.0%
3.42
US$513,600 		150,000 +4.0% 3.42 US$513,600
2021-05-05 2021-05-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
2,500 -43.9%
26.64
US$66,602 		2,500 -43.9% 26.64 US$66,602
2021-04-13 2021-04-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
4,078 -32.7%
25.00
US$101,950 		4,078 -32.7% 25.00 US$101,950
2021-04-07 2021-04-05 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
2,500 -43.9%
25.54
US$63,848 		2,500 -43.9% 25.54 US$63,848
2021-03-16 2021-03-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
4,078 -32.7%
26.36
US$107,493 		4,078 -32.7% 26.36 US$107,493
2021-03-04 2021-03-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
884 -21.6%
26.57
US$23,484 		884 -21.6% 26.57 US$23,484
2021-03-04 2021-03-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
1,616 -28.4%
25.85
US$41,778 		1,616 -28.4% 25.85 US$41,778
2021-02-12 2021-02-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
307 -3.5%
27.66
US$8,492 		307 -3.5% 27.66 US$8,492
2021-02-12 2021-02-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
3,771 -30.2%
27.19
US$102,533 		3,771 -30.2% 27.19 US$102,533
2021-02-04 2021-02-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
2,500 -43.9%
25.35
US$63,375 		2,500 -43.9% 25.35 US$63,375
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
7,511 -47.2%
36.00
US$270,395 		7,511 -47.2% 36.00 US$270,395
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
100 -0.6%
34.13
US$3,412 		100 -0.6% 34.13 US$3,412
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
103 -0.6%
32.50
US$3,347 		103 -0.6% 32.50 US$3,347
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
147 -0.9%
31.91
US$4,690 		147 -0.9% 31.91 US$4,690
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
1,669 -9.3%
30.50
US$50,912 		1,669 -9.3% 30.50 US$50,912
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
2,048 -10.3%
29.92
US$61,284 		2,048 -10.3% 29.92 US$61,284
2021-01-11 2021-01-08 PlS Planned sale
2.4
Leggett Thomas

Chief Financial Officer

Officer
3,000 -100.0%
33.94
US$101,820 		3,000 -100.0% 33.94 US$101,820
2021-01-06 2021-01-04 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
537 -14.4%
31.78
US$17,065 		537 -14.4% 31.78 US$17,065
2021-01-06 2021-01-04 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
1,963 -34.4%
31.31
US$61,460 		1,963 -34.4% 31.31 US$61,460
2021-01-06 2021-01-04 PlS Planned sale
Epstein David M.

See Remarks

Executive Director
2,015 -0.3%
31.80
US$64,075 		2,015 -0.3% 31.80 US$64,075
2021-01-06 2021-01-04 PlS Planned sale
Epstein David M.

See Remarks

Executive Director
9,985 -1.4%
30.99
US$309,430 		9,985 -1.4% 30.99 US$309,430
2020-12-16 2020-12-14 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
4,078 -57.6%
34.95
US$142,522 		4,078 -57.6% 34.95 US$142,522
2020-12-10 2020-12-08 PlS Planned sale
2.4
Leggett Thomas

Chief Financial Officer

Officer
1,941 -100.0%
34.05
US$66,094 		1,941 -100.0% 34.05 US$66,094
2020-12-10 2020-12-08 PlS Planned sale
2.4
Leggett Thomas

Chief Financial Officer

Officer
1,059 -35.3%
33.27
US$35,233 		1,059 -35.3% 33.27 US$35,233
2020-12-04 2020-12-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
2,500 -100.0%
32.42
US$81,055 		2,500 -100.0% 32.42 US$81,055
2020-12-03 2020-12-01 PlS Planned sale
Epstein David M.

See Remarks

Executive Director
1,077 -0.2%
33.45
US$36,021 		1,077 -0.2% 33.45 US$36,021
2020-12-03 2020-12-01 PlS Planned sale
Epstein David M.

See Remarks

Executive Director
10,923 -1.5%
32.64
US$356,553 		10,923 -1.5% 32.64 US$356,553
2020-12-01 2020-11-30 PlS Planned sale
3.2
Bolzon Bradley J PhD
Non-Executive Director Large shareholder
200 -0.0%
34.16
US$6,833 		200 -0.0% 34.16 US$6,833
2020-12-01 2020-11-30 PlS Planned sale
3.2
Bolzon Bradley J PhD
Non-Executive Director Large shareholder
10,193 -1.2%
33.13
US$337,680 		10,193 -1.2% 33.13 US$337,680
2020-12-01 2020-11-30 PlS Planned sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
200 -0.0%
34.16
US$6,833 		200 -0.0% 34.16 US$6,833
2020-12-01 2020-11-30 PlS Planned sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
10,193 -1.2%
33.13
US$337,680 		10,193 -1.2% 33.13 US$337,680

See older Black Diamond Therapeutics Inc insider trades

Plus unlocks the full transaction history.

See localized pricing at checkout
Unlock Black Diamond Therapeutics Inc history with Plus

Billed monthly · Cancel anytime

Explore more

More insider trading research around Black Diamond Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America